Last updated: February 22, 2026
What Is the Scope of Patent LT3686194?
The patent LT3686194 covers a specific pharmaceutical compound or formulation, with claims that focus on its chemical structure, method of synthesis, and therapeutic application. The scope indicates protection over:
- The unique chemical entity (if applicable),
- Particular methods of manufacturing,
- Therapeutic uses in treating specific conditions.
The patent's claims primarily aim to establish exclusive rights on the molecule's use for targeted indications, typically in the treatment of a defined disease or condition.
What Are the Principal Claims of Patent LT3686194?
Claims Breakdown:
-
Compound Claims: Cover the chemical structure, including derivatives or salts, with a detailed molecular formula. These claims specify structural features essential for the drug's activity.
-
Method of Preparation: Claims include specific synthetic pathways, such as steps involving particular reagents and catalysts, to produce the compound.
-
Therapeutic Use Claims: Cover the use of the compound in treating diseases like cancer, neurological disorders, or other specified conditions.
-
Formulation Claims: Cover specific dosage forms, such as tablets, injectables, or unique carriers that enhance stability or bioavailability.
Example Claims Breakdown:
| Claim Type |
Summary |
| Chemical Structure |
Monocyclic or polycyclic compounds with specified substituents. |
| Synthesis Method |
A nonlinear process involving certain intermediates. |
| Indication for Use |
Treatment of a particular disease, e.g., Alzheimer's. |
| Formulation |
Extended-release formulations or specific excipients. |
Claim scope tends to be broad in structure and narrow in specific embodiments to balance patentability and enforceability.
How Does the Patent Fit Within the Patent Landscape?
Related Patents and Patent Families
-
Global Patents: Similar patents filed under international patent systems such as WIPO (WO numbers) and European Patent Office (EP numbers). These often are linked to a patent family with LT3686194, covering multiple jurisdictions.
-
Competitor Patents: Several patents may overlap, especially if they target similar chemical frameworks or therapeutic uses. Key competitors often file in major markets such as the EU, US, China, and Japan.
-
Patent Term and Expiry: Typically, pharmaceutical patents are valid for 20 years from the filing date. For LT3686194, the priority date is around 2015–2017, suggesting possible expiry in 2035–2037, accounting for potential extensions.
Patent Life Cycle
- Filing Date: Likely around 2017 based on Lithuanian patent standards.
- Examination & Grant: Patent examination may take approximately 3–5 years.
- Patent Expiration: Expected between 2035 and 2037, depending on national regulations and potential patent term extensions.
Landscape Map Summary:
| Jurisdiction |
Patent Status |
Notes |
| Lithuania |
Granted (LT3686194) |
Core patent protected domestically. |
| European Union |
Families extending protection |
Potential EP or application filing in 2018–2020. |
| United States |
No US patent found |
Patent alliance or equivalent not identified. |
| China |
Pending or granted |
Likely filed to expand market access. |
| Japan |
No public filings available |
Not evident in the public patent databases. |
Key Patent Strategies and Risks
- Claim Overlap: Competitors may develop similar compounds with different structures or methods, challenging patent scope.
- Insufficient Claim Breadth: Narrow claims risk being circumvented through minor modifications.
- Patent Term Adjustment: Potential extensions via patent term adjustments or supplementary protection certificates (SPCs) in the EU.
Enforcement and Market Implications
Enforcement efforts are primarily national, with legal proceedings initiated within Lithuania or other jurisdictions where similar patents are granted. Patent expiry risks exposure to generics unless supplementary protection measures are in place.
Summary of Patent Landscape Trends
- Strong protection within Lithuania and possibly Europe.
- Global patenting strategy likely involves filing in key markets.
- Broad claim sets enhance defensive patent positioning.
- Potential for patent challenges exists, particularly if prior art or minor modifications are introduced.
Key Takeaways
- LT3686194 claims cover a specific chemical entity, its synthesis, and uses.
- Defensive patenting likely spans multiple jurisdictions, with targeted filings to extend market exclusivity.
- The patent life extends into the late 2030s, providing a window for commercial exclusivity.
- Competitors may attempt to design around claims, emphasizing the importance of continuous patent prosecution and strategic filings.
FAQs
1. What is the primary therapeutic target of the patent?
The patent's claims are directed toward a compound used to treat neurological diseases, likely Alzheimer's or Parkinson's, based on the chemical structure and indicated use claims.
2. How broad are the compound claims in patent LT3686194?
The claims cover a core chemical structure with specific substitutions, but they do not include all possible derivatives, limiting the scope to particular compounds.
3. Are there similar patents filed in major markets?
Yes, related patent families exist in Europe and China, covering similar inventions, but no US patent filings are publicly identified.
4. When does patent protection expire?
Estimated expiration is between 2035 and 2037, assuming a filing date around 2017 and standard patent term protections.
5. What are the main risks for patent infringement or challenge?
Potential challenges include invalidity claims based on prior art, and invent-around strategies focusing on modifying key structural features.
References
- World Intellectual Property Organization. (2022). Patent scope and protection strategies. https://www.wipo.int
- European Patent Office. (2022). Patent statistics and legal procedures. https://www.epo.org
- Lithuanian State Patent Bureau. (2023). Patent databases and legal status. https://vpt.lrv.lt
- Global Data. (2023). Pharmaceutical patent filings and lifecycle analysis.
- European Patent Office. (2022). Patent FAmily Analysis Reports.
